New!
$Adverum Biotechnologies(ADVM.US$ Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients With Wet AMD at AAO 2023
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden -
- 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 -
- Durable aflibercept protein levels up to 4.5 years after a single Ixo-vec IVT injection -
- Ixo-vec continues to be generally well tolerated -
- Previously announced aflibercept protein levels from the LUNA study were also presented -![]()
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden -
- 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 -
- Durable aflibercept protein levels up to 4.5 years after a single Ixo-vec IVT injection -
- Ixo-vec continues to be generally well tolerated -
- Previously announced aflibercept protein levels from the LUNA study were also presented -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
QianmengYu : great news! safety is main concern for gene therapy.
TrytosaveabitOP QianmengYu: Absolutely! GL